Introduction
============

The number of people with type 2 diabetes is estimated to be 422 million globally and is projected to reach 642 million by 2040,[@ref1] [@ref2] imposing a substantial disease toll and economic burden on patients and healthcare systems. Cardiovascular disease is the leading cause of deaths in adults with diabetes.[@ref3] Current dietary guidelines for the prevention and management of cardiovascular disease among patients with diabetes recommend limited intake of saturated fatty acids, trans fats, and cholesterol and higher consumption of foods abundant in omega-3 polyunsaturated fatty acids (PUFAs),[@ref4] such as fish, nuts, and seeds. However, these recommendations were largely based on findings from general populations. Owing to the altered metabolism of carbohydrates and fats,[@ref5] dyslipidemia, and the prothrombotic profile in patients with diabetes,[@ref6] whether the recommendations could be extrapolated to these patients has yet to be elucidated. The risk of cardiovascular disease among patients with type 2 diabetes is two to three times that among general populations, so the health effects of dietary fats, especially omega-3 PUFAs, in these patients needs to be clarified.[@ref7] A Mediterranean diet rich in monounsaturated or polyunsaturated fats has been shown to improve blood glucose and lipid control among people with diabetes,[@ref8] [@ref9] [@ref10] [@ref11] but the association between dietary fats and total mortality or mortality due to cardiovascular disease in such population remains unclear.[@ref12] [@ref13] [@ref14] [@ref15]

To fill this knowledge gap, we assessed the associations of major dietary fats with cardiovascular disease mortality and total mortality among adults with diabetes in two large prospective cohort studies. We hypothesized that quality of fats determines their associations with total and cardiovascular disease mortality among patients with type 2 diabetes.

Methods
=======

Study population
----------------

The Nurses' Health Study (NHS) is an ongoing cohort study consisting of 121 701 female nurses aged 30-55 years at enrollment in 1976.[@ref16] The Health Professionals Follow-Up Study (HPFS) is a parallel cohort that started in 1986 and enrolled 51 529 US male health professionals aged 40-75 years.[@ref17] Details of these two cohorts have been published elsewhere.[@ref17] [@ref18] Information on non-dietary lifestyle factors, medical history, and incident diseases was collected every two years through validated questionnaires.[@ref19] The cumulative response rate during follow-up was more than 90% in both cohorts. The return of completed questionnaires was considered to imply informed consent.

The analysis reported here included both prevalent cases of type 2 diabetes at study baseline (1980 for NHS or 1986 for HPFS when dietary data were first collected) and incident cases diagnosed during follow-up. We excluded participants who had cardiovascular disease or cancer at baseline or before diagnosis of type 2 diabetes, had implausible daily caloric intake (\<500 or \>3500 kcal/day for women; \<800 or \>4200 kcal/day for men), or had missing data of dietary fats at the entry of our analysis. The final sample included 1498 prevalent cases and 9766 incident cases (supplementary figure A).

Ascertainment of type 2 diabetes
--------------------------------

Participants with a self reported diagnosis of diabetes were sent a validated supplementary questionnaire to obtain detailed information on the diabetes diagnosis, including date of diagnosis, symptoms, and treatment. Before 1997 cases of type 2 diabetes were diagnosed according to the original National Diabetes Data Group criteria if they met at least one of the following criteria: classic symptoms plus a fasting plasma glucose concentration of 140 mg/dL (7.8 mmol/L) or above or a randomly measured plasma glucose concentration of 200 mg/dL (11.1 mmol/L) or above; at least two elevated plasma glucose concentrations on different occasions (≥140 mg/dL for fasting glucose or ≥200 mg/dL for randomly measured glucose; ≥200 mg/dL for at least two hours after an oral glucose challenge); or treatment with hypoglycemic drugs (insulin or an oral hypoglycemic agent).[@ref20] From 1997 the fasting plasma glucose concentration for diagnosis of diabetes was lowered to 7.0 mmol/L or 126 mg/dL on the basis of the American Diabetes Association diagnostic criteria.[@ref21] In validation studies, 98% of cases of diabetes reported by questionnaire were reconfirmed by medical record review in the NHS,[@ref22] and 97% of cases were re-confirmed in the HPFS.[@ref23] Given such high accuracy, we included all self reported cases of diabetes to increase the sample size.

Dietary assessment
------------------

Diet was assessed using validated semiquantitative food frequency questionnaires (FFQs) administered in 1980, 1984, 1986, and every four years thereafter in the NHS and every four years since 1986 in the HPFS, as described previously.[@ref24] [@ref25] The overall validity and reliability of the semiquantitative FFQs have been reported previously.[@ref24] [@ref25] Nutrient composition came from the Harvard University Food Composition Database, which is continuously updated to account for changes in nutrient contents and food processing. Fat intake was then calculated by multiplying the consumption frequency of each food item with a pre-specified portion size (for example, one egg or one slice of bread) by the content of fats, taking account of the brand and type of fat used in preparation. Dietary fats were expressed as percentages of energy. We calculated cumulative averages of dietary variables over all valid assessments from the first dietary questionnaire after diagnosis of type 2 diabetes through the FFQ assessment made before the incidence of cardiovascular disease. In comparison with use of baseline dietary assessments only or updating the diet during follow-up using each FFQ assessment in isolation, using the cumulative averages helps to reduce within person variability and provide more stable estimate of long term diet,[@ref26] which is more biologically relevant to incidence of chronic disease. We stopped updating diet after a diagnosis of incident cardiovascular disease or cancer during study follow-up to minimize the possibility of reverse causation bias---patients with these conditions may adapt to a healthier diet but are still at a higher mortality risk than those without these conditions, and therefore a healthy diet may seem to be associated with early death if we continued to update their lifestyle/diet after the incidence of diseases.

In validation studies, the assessment of dietary fats was compared with that estimated by multiple one week diet records. Correlation coefficients between fat intakes assessed by the 1986 FFQ and diet records were 0.70 for saturated fatty acids, 0.69 for monounsaturated fatty acids (MUFAs), and 0.64 for PUFAs.[@ref27]

Covariate assessments
---------------------

Information on lifestyle and other potential risk factors for mortality was assessed at baseline and updated during follow-up through biennial questionnaires, including age, ethnicity, weight, smoking status, alcohol intake, physical activity, family history of diabetes, family history of myocardial infarction, self reported hypertension and hypercholesterolemia, use of multivitamin, use of aspirin, and use of insulin and oral hypoglycemic drugs. Body mass index was calculated by dividing weight (kg) by height squared (m^2^). Physical activity was assessed as hours per week of moderate or vigorous activities (including brisk walking) that require the expenditure of at least 3 metabolic equivalents (METs) or more per hour.[@ref28]

Ascertainment of deaths
-----------------------

We identified deaths by searching the National Death Index and through reports by next of kin or postal authorities.[@ref29] More than 98% of deaths were identified.[@ref30] The cause of death was ascertained by physicians who were blinded to the risk profiles of the participants through review of death certificates and medical records. We used ICD-8 (international classification of diseases, 8th revision) and ICD-9 codes to classify cardiovascular mortality (ICD-8: 390.0-458.9; ICD-9: 390.0-459.9) and cancer mortality (ICD-8: 140.0-207.9; ICD-9: 140.0-208.9).[@ref31]

Statistical analysis
--------------------

We calculated person time from the return date of the first dietary questionnaire after diagnosis of type 2 diabetes to the time of death or the end of follow-up (June 30, 2014 for the NHS and January 30, 2014 for the HPFS), whichever was earlier. We applied Cox proportional hazards models to estimate hazard ratios and 95% confidence intervals for the associations of different dietary fats with cardiovascular disease, cancer, and total mortality. To ensure a large enough number of deaths for analyses, we pooled participants from the two cohorts (no significant heterogeneity was found).

We built several isocaloric models to estimate relative risk of deaths when energy from saturated fats or carbohydrates was theoretically replaced by equivalent energy from another macronutrient. A key rationale of the substitution analysis is that, in the isocaloric setting, the reduction of one macronutrient as a percentage of total energy intake will be replaced by the same proportion of energy from another macronutrient, when total energy intake and intake of all other macronutrients are held constant.[@ref32] For example, to model the association with mortality when energy from carbohydrates is isocalorically replaced by PUFAs, we included PUFAs, total energy, monounsaturated fats, saturated fats, trans fats, and proteins in the multivariate model. In such a model, the β coefficient of PUFAs bears interpretation as the theoretical effect of substituting PUFAs for the same amount of energy from carbohydrates. To make the risk estimates comparable for various macronutrient substitution analyses, we present results for 2% energy substitution, which is more realistic for macronutrients at low intake levels (or example, 1-2% energy for trans fat). For specific PUFAs, such as arachidonic acid and marine n-3 PUFAs, with even lower intake levels (0.1-0.2% energy), we used a smaller proportion of energy (0.1%). Other covariates in the substitution analysis included age, sex, ethnicity, body mass index at diagnosis, smoking status, pack years of smoking, physical activity, alcohol consumption, family history of diabetes or myocardial infarction, self reported hypertension or hypercholesterolemia, duration of diabetes, multivitamin use, current aspirin use, and dietary cholesterol intake. We calculated tests for trend by modeling the median values of each category as a continuous variable.

In a secondary analysis, we further analyzed the associations for MUFAs from plant and animal origins separately. We did sensitivity analyses by excluding mortality that occurred within four years after diagnosis of diabetes, excluding prevalent type 2 diabetes, excluding participants with extreme body mass index (\<18.5 or \>40.0), restricting the analysis to only confirmed cases of type 2 diabetes, or further adjusting for the use of lipid lowering or hypoglycemic drugs.

We used SAS 9.4 for statistical analyses. We considered two sided P values below 0.05 to be statistically significant.

Patient and public involvement
------------------------------

Participants were not involved in setting the research question or the outcome measures, nor were they involved in developing plans for recruitment, design, or implementation of the study. No participants were asked to advise on interpretation or writing up of the manuscript. The participants are updated on the study outcomes and developments through the study websites ([www.nurseshealthstudy.org](http://www.nurseshealthstudy.org) and <https://www.hsph.harvard.edu/hpfs/index.html>) and newsletters.

Results
=======

Population characteristics
--------------------------

The sources of dietary fats, in particular trans fat, changed over time during follow-up,[@ref33] such that margarine was one of the primary sources of both trans fats and PUFAs in early, but not later, follow-up. Given this time trend, we show the characteristics of patients at the midpoint of follow-up. During a mean follow-up of 11 years (124 362 person years), we documented 2502 deaths, including 646 deaths due to cardiovascular disease. At the midpoint of follow-up, women with higher PUFA intake tended to be older, had shorter duration of diabetes, and were less likely to have a family history of cancer than women with lower PUFA consumption. In addition, higher PUFA intake was correlated with lower intake of carbohydrates or trans fat but higher intake of MUFAs ([table 1](#tbl1){ref-type="table"}). Men with higher PUFA consumption tended to be younger and had higher pack years of smoking. Similarly, in men, higher PUFA intake was correlated with lower intake of carbohydrate and higher intakes of saturated fatty acids and MUFAs. Participants' characteristics according to saturated fatty acid and MUFA intake are shown in supplementary table A.

###### 

Characteristics of participants at midpoint of follow-up. Values are numbers (percentages) unless stated otherwise

  Characteristics                                        Quarters of polyunsaturated fat intake (% energy)                                     
  ------------------------------------------------------ --------------------------------------------------- ---------------- ---------------- ----------------
  **Nurses' Health Study (n=9053)**                      **(n=2358)**                                        **(n=2275)**     **(n=2224)**     **(n=2196)**
  Mean (SD) age, years                                   69.7 (10.6)                                         72.6 (8.4)       73.1 (7.3)       73.6 (7.2)
  White ethnicity                                        2200 (93.3)                                         2230 (98.0)      2184 (98.2)      2154 (98.1)
  Age adjusted mean (SD) body mass index                 29.4 (6.8)                                          29.3 (7.1)       30.3 (6.4)       28.9 (5.5)
  Age adjusted mean (SD) alcohol consumption, g/day      3.8 (8.9)                                           3.3 (6.7)        3.5 (7.9)        3.7 (7.7)
  Age adjusted mean (SD) physical activity, h/week       1.0 (2.2)                                           1.9 (3.4)        1.2 (2.8)        1.8 (3.2)
  Current smoker                                         391 (16.6)                                          141 (6.2)        176 (7.9)        182 (8.3)
  Age adjusted mean (SD) pack years' smoking             336.6 (444.7)                                       434.2 (471.2)    407.0 (461.3)    509.7 (471.8)
  Multivitamin use                                       1139 (48.3)                                         1240 (54.5)      1305 (58.7)      1269 (57.8)
  Family history of diabetes                             1113 (47.2)                                         858 (37.7)       832 (37.4)       898 (40.9)
  Family history of myocardial infarction                729 (30.9)                                          669 (29.4)       483 (21.7)       525 (23.9)
  Family history of cancer                               394 (16.7)                                          355 (15.6)       282 (12.7)       184 (8.4)
  Aspirin use                                            1101 (46.7)                                         1279 (56.2)      1285 (57.8)      1228 (55.9)
  Hypoglycemic drug use                                  1205 (51.1)                                         1413 (62.1)      1466 (65.9)      1377 (62.7)
  Age adjusted mean (SD) duration of diabetes, years     3.5 (2.1)                                           3.5 (2.3)        3.4 (1.8)        3.2 (1.5)
  Hypercholesterolemia                                   1743 (73.9)                                         1859 (81.7)      1750 (78.7)      1810 (82.4)
  Hypertension                                           2122 (90.0)                                         2073 (91.1)      2051 (92.2)      1957 (89.1)
  Age adjusted mean (SD) total energy intake, kcal/day   1561.9 (527.4)                                      1618.5 (471.4)   1612.0 (451.1)   1603.6 (520.4)
  Age adjusted mean (SD) intakes, % energy:                                                                                                    
   Carbohydrates                                         53.8 (9.2)                                          50.9 (8.9)       49.8 (6.8)       46.2 (6.4)
   Protein                                               18.8 (3.8)                                          18.6 (3.5)       18.1 (2.9)       17.9 (3.2)
   Total fats                                            27.4 (6.5)                                          31.0 (6.0)       32.6 (5.2)       36.4 (5.5)
   Total PUFAs                                           4.4 (0.7)                                           5.8 (0.3)        6.8 (0.3)        9.4 (2.2)
   n-3 PUFAs                                             0.6 (0.2)                                           0.7 (0.2)        0.9 (0.2)        1.2 (0.5)
   α-linolenic acid                                      0.5 (0.1)                                           0.6 (0.1)        0.7 (0.2)        1.0 (0.5)
   Marine n-3 PUFAs                                      0.1 (0.1)                                           0.2 (0.2)        0.2 (0.2)        0.2 (0.2)
   n-6 PUFAs                                             3.9 (0.9)                                           5.1 (0.7)        6.1 (0.6)        8.3 (1.9)
   Linoleic acid                                         3.8 (0.9)                                           5.0 (0.7)        6.0 (0.6)        8.2 (1.9)
   Arachidonic acid                                      0.1 (0.0)                                           0.1 (0.0)        0.1 (0.0)        0.1 (0.0)
   Saturated fatty acids                                 10.3 (3.4)                                          10.7 (3.3)       10.9 (2.8)       10.7 (2.6)
   Monounsaturated fatty acids                           10.1 (3.0)                                          11.9 (3.4)       12.0 (2.8)       13.5 (3.0)
   Trans fats                                            1.3 (0.5)                                           1.2 (0.7)        1.1 (0.6)        1.0 (0.7)
  **Health Professionals Follow-up Study (n=2211)**      **(n=476)**                                         **(n=539)**      **(n=582)**      **(n=614)**
  Mean (SD) age, years                                   75.0 (9.9)                                          74.1 (9.3)       72.1 (8.0)       71.8 (6.4)
  White ethnicity                                        419 (88.0)                                          497 (92.3)       539 (92.6)       573 (93.3)
  Age adjusted mean (SD) body mass index                 26.9 (3.9)                                          29.3 (4.7)       27.9 (4.5)       27.9 (4.1)
  Age adjusted mean (SD) alcohol consumption, g/day      15.3 (19.0)                                         13.2 (15.0)      8.4 (8.5)        10.0 (11.8)
  Age adjusted mean (SD) physical activity, h/week       2.4 (3.2)                                           5.4 (17.2)       3.5 (5.2)        6.1 (10.0)
  Current smoker                                         16 (3.3)                                            9 (1.6)          53 (9.1)         24 (3.9)
  Age adjusted mean (SD) pack years' smoking             193.5 (327.8)                                       265.5 (410.4)    308.1 (410.3)    328.1 (423.7)
  Multivitamin use                                       264 (55.4)                                          294 (54.6)       342 (58.8)       355 (57.8)
  Family history of diabetes                             246 (51.7)                                          160 (29.6)       100 (17.2)       269 (43.8)
  Family history of myocardial infarction                218 (45.7)                                          176 (32.6)       158 (27.1)       193 (31.5)
  Family history of cancer                               99 (20.9)                                           209 (38.7)       250 (43.0)       226 (36.8)
  Aspirin use                                            306 (64.2)                                          309 (57.4)       332 (57.0)       371 (60.5)
  Hypoglycemic drug use                                  153 (32.2)                                          156 (29.0)       177 (30.4)       279 (45.4)
  Age adjusted mean (SD) duration of diabetes, years     3.0 (0.8)                                           3.2 (0.8)        3.1 (1.0)        3.2 (1.5)
  Hypercholesterolemia                                   317 (66.7)                                          434 (80.6)       442 (76.0)       432 (70.4)
  Hypertension                                           361 (75.9)                                          470 (87.2)       443 (76.1)       468 (76.2)
  Age adjusted mean (SD) total energy intake, kcal/day   1763.8 (447.3)                                      1908.2 (478.1)   1778.6 (559.0)   2141.4 (739.7)
  Age adjusted mean (SD) intakes, % energy:                                                                                                    
   Carbohydrates                                         51.5 (8.0)                                          47.8 (6.1)       47.2 (7.0)       43.0 (7.0)
   Protein                                               18.0 (3.3)                                          18.4 (4.3)       18.4 (3.2)       18.5 (2.9)
   Total fats                                            27.1 (4.8)                                          30.5 (4.8)       32.9 (5.3)       37.7 (6.2)
   Total PUFAs                                           4.5 (0.5)                                           5.8 (0.3)        6.8 (0.3)        9.6 (2.6)
   n-3 PUFAs                                             0.6 (0.2)                                           0.7 (0.3)        0.8 (0.2)        1.3 (0.6)
   α-linolenic acid                                      0.4 (0.1)                                           0.5 (0.2)        0.6 (0.2)        1.0 (0.5)
   Marine n-3 PUFAs                                      0.2 (0.1)                                           0.2 (0.2)        0.2 (0.1)        0.3 (0.2)
   n-6 PUFAs                                             4.2 (0.6)                                           5.1 (0.5)        6.2 (0.5)        8.5 (2.1)
   Linoleic acid                                         4.1 (0.6)                                           5.0 (0.5)        6.1 (0.5)        8.4 (2.1)
   Arachidonic acid                                      0.1 (0.0)                                           0.1 (0.0)        0.1 (0.0)        0.1 (0.0)
   Saturated fatty acids                                 9.8 (2.4)                                           10.3 (2.8)       10.4 (2.6)       10.5 (2.3)
   Monounsaturated fatty acids                           10.2 (2.1)                                          11.7 (2.1)       12.7 (2.7)       14.5 (3.4)
   Trans fats                                            1.1 (0.5)                                           1.4 (0.7)        1.2 (0.6)        1.1 (0.8)

PUFA=polyunsaturated fatty acids.

Cardiovascular and total mortality
----------------------------------

We observed a significant inverse association of total PUFAs with cardiovascular disease mortality and total mortality after adjusting for age and sex ([table 2](#tbl2){ref-type="table"} **)**. In a multivariate adjusted model that estimated mortality risk by substituting fats for carbohydrates, the association remained significant: hazard ratios across quarters of PUFA intake (from low to high) were 1.00, 0.99 (95% confidence interval 0.80 to 1.23), 0.85 (0.67 to 1.08), and 0.76 (0.58 to 0.99) for cardiovascular disease mortality (P for trend=0.03) and 1.00, 0.86 (0.77 to 0.95), 0.83 (0.74 to 0.94), and 0.68 (0.60 to 0.78) for total mortality (P for trend\<0.001). Intakes of saturated fatty acids and trans fats were positively associated with cardiovascular disease mortality in the age and sex adjusted model (model 1) but became non-significant after adjustment for other covariates (model 2; [table 2](#tbl2){ref-type="table"}).

###### 

Associations of dietary fats with cardiovascular disease mortality and total mortality among adults with type 2 diabetes mellitus. Values are hazard ratios (95% CIs) unless stated otherwise

                                             Quarters of fatty acids intake   P for trend                                                       
  ------------------------------------------ -------------------------------- --------------------- --------------------- --------------------- ---------
  **Polyunsaturated fat intake**                                                                                                                
  Median (range) % energy                    4.48 (≤5.06)                     5.50 (5.07-5.97)      6.39 (5.98-7.06)      7.95 (≥7.07)          
  Cardiovascular disease mortality:                                                                                                             
   No of cases/person years                  198/31 335                       176/31 490            147/31 569            125/31 600            
   Model 1[\*](#t2n1){ref-type="table-fn"}   1.00                             0.98 (0.79 to 1.20)   0.84 (0.67 to 1.04)   0.74 (0.59 to 0.93)   0.004
   Model 2[†](#t2n2){ref-type="table-fn"}    1.00                             0.99 (0.80 to 1.23)   0.85 (0.67 to 1.08)   0.76 (0.58 to 0.99)   0.03
  Total mortality:                                                                                                                              
   No of cases/person years                  855/30 754                       627/31 082            575/31 189            445/31 336            
   Model 1[\*](#t2n1){ref-type="table-fn"}   1.00                             0.81 (0.73 to 0.90)   0.78 (0.70 to 0.86)   0.61 (0.55 to 0.69)   \<0.001
   Model 2[†](#t2n2){ref-type="table-fn"}    1.00                             0.86 (0.77 to 0.95)   0.83 (0.74 to 0.94)   0.68 (0.60 to 0.78)   \<0.001
  **Monounsaturated fatty acids**                                                                                                               
  Median (range) % energy                    9.51 (≤10.77)                    11.66 (10.78-12.61)   13.37 (12.62-14.64)   16.01 (≥14.65)        
  Cardiovascular disease mortality:                                                                                                             
   No of cases/person years                  160/31 453                       163/31 524            151/31 559            172/31 458            
   Model 1[\*](#t2n1){ref-type="table-fn"}   1.00                             1.08 (0.87 to 1.35)   1.05 (0.84 to 1.32)   1.31 (1.05 to 1.64)   0.02
   Model 2[†](#t2n2){ref-type="table-fn"}    1.00                             0.96 (0.74 to 1.24)   0.85 (0.63 to 1.15)   0.99 (0.70 to 1.39)   0.97
  Total mortality:                                                                                                                              
   No of cases/person years                  694/30 975                       635/31 088            580/31 203            593/31 096            
   Model 1[\*](#t2n1){ref-type="table-fn"}   1.00                             1.01 (0.90 to 1.12)   0.97 (0.87 to 1.09)   1.08 (0.97 to 1.21)   0.23
   Model 2[†](#t2n2){ref-type="table-fn"}    1.00                             0.93 (0.82 to 1.05)   0.83 (0.72 to 0.96)   0.90 (0.76 to 1.06)   0.21
  **Saturated fatty acids**                                                                                                                     
  Median (range) % energy                    8.03 (≤9.28)                     10.03 (9.29-11.09)    11.69 (11.10-13.18)   14.34 (≥13.19)        
  Cardiovascular disease mortality:                                                                                                             
   No of cases/person years                  138/31 501                       166/31 535            154/31 558            188/31 400            
   Model 1[\*](#t2n1){ref-type="table-fn"}   1.00                             1.30 (1.03 to 1.64)   1.26 (1.00 to 1.59)   1.71 (1.37 to 2.14)   \<0.001
   Model 2[†](#t2n2){ref-type="table-fn"}    1.00                             1.14 (0.88 to 1.48)   0.98 (0.73 to 1.33)   1.13 (0.80 to 1.59)   0.62
  Total mortality:                                                                                                                              
   No of cases/person years                  594/31 087                       628/31 103            613/31 184            667/30 988            
   Model 1[\*](#t2n1){ref-type="table-fn"}   1.00                             1.14 (1.02 to 1.28)   1.21 (1.08 to 1.36)   1.39 (1.24 to 1.56)   \<0.001
   Model 2[†](#t2n2){ref-type="table-fn"}    1.00                             1.05 (0.92 to 1.19)   1.03 (0.89 to 1.19)   1.00 (0.85 to 1.19)   0.88
  **Trans fatty acids**                                                                                                                         
  Median (range) % energy                    0.94 (≤1.16)                     1.37 (1.17-1.53)      1.71 (1.54-1.95)      2.24 (≥1.96)          
  Cardiovascular disease mortality:                                                                                                             
   No of cases/person years                  140/31 499                       149/31 542            165/31 546            192/31 407            
   Model 1[\*](#t2n1){ref-type="table-fn"}   1.00                             1.10 (0.87 to 1.39)   1.25 (0.99 to 1.57)   1.49 (1.19 to 1.86)   \<0.001
   Model 2[†](#t2n2){ref-type="table-fn"}    1.00                             0.97 (0.76 to 1.25)   1.03 (0.80 to 1.34)   1.13 (0.86 to 1.50)   0.28
  Total mortality:                                                                                                                              
   No of cases/person years                  558/31 131                       574/31 176            638/31 115            732/30 940            
   Model 1[\*](#t2n1){ref-type="table-fn"}   1.00                             1.06 (0.94 to 1.19)   1.21 (1.08 to 1.36)   1.42 (1.27 to 1.58)   \<0.001
   Model 2[†](#t2n2){ref-type="table-fn"}    1.00                             0.93 (0.82 to 1.06)   1.01 (0.88 to 1.15)   1.08 (0.94 to 1.25)   0.11

Adjusted for age (in months), sex, and survey period.

Further adjusted for ethnicity (white, others), body mass index at diagnosis (\<23.0, 23.0-24.9, 25.0-29.9, 30.0-34.9, ≥35.0), physical activity (0-0.4, 0.5-1.9, 2.0-3.4, 3.5-5.4, ≥5.5 h/week), smoking status (never, past, current 1-14 cigarettes/d, current ≥15 cigarettes/d), smoking pack years (0, \<20, ≥20 pack years), alcohol consumption (0, 0.1-4.9, 5.0-14.9, 15.0-29.9, ≥30.0 g/d), multivitamin use (yes, no), current aspirin use (yes, no), family history of myocardial infarction (yes, no), family history of diabetes (yes, no), history of hypercholesterolemia (yes, no), history of hypertension (yes, no), duration of diabetes (\<5, 5-10, \>10 years), total energy intake (quarters), dietary cholesterol (quarters), and percentage of energy from dietary protein and remaining fatty acids where appropriate (polyunsaturated fatty acids (PUFAs), monounsaturated fatty acids, trans fats, linoleic acid, arachidonic acid, α-linolenic acid, and marine n-3 PUFAs; all continuous variables). In this model, the β coefficients of dietary fats bear meaning of effects of isocalorically substituting for total carbohydrates.

Total MUFA intake was not significantly associated with either cardiovascular disease mortality or total mortality (model 2; [table 2](#tbl2){ref-type="table"}). Nevertheless, MUFAs from animal sources (mainly red meats and high fat dairy products) were positively associated with total mortality (hazard ratio comparing the highest versus lowest quarters 1.23, 1.04 to 1.45; P for trend\<0.001; supplementary table B) and non-significantly associated with a higher cardiovascular disease mortality (hazard ratio 1.27, 0.92 to 1.75; P for trend=0.07). We found no significant associations with mortality for intake of plant derived MUFAs.

For specific PUFAs, intake of marine n-3 PUFAs was associated with a lower cardiovascular mortality after multivariate adjustment (hazard ratio comparing extreme quarters 0.69, 0.52 to 0.90; P for trend=0.007). The association between linoleic acid and cardiovascular disease mortality did not achieve statistical significance, with a hazard ratio of 0.75 (0.56 to 1.01; P for trend=0.06) ([table 3](#tbl3){ref-type="table"}). Intake of marine n-3 PUFAs and linoleic acid was associated with lower total mortality: hazard ratios comparing extreme quarters were 0.71 (0.62 to 0.82; P for trend\<0.001) and 0.81 (0.69 to 0.94; P for trend=0.008), respectively ([table 3](#tbl3){ref-type="table"}). Intake of α-linolenic acid was non-significantly associated with lower total mortality (hazard ratio 0.88, 0.76 to 1.02; P for trend=0.04).

###### 

Cardiovascular disease mortality and total mortality among adults with type 2 diabetes mellitus by isocaloric substitution of specific polyunsaturated fatty acids (PUFAs) for total carbohydrates. Values are hazard ratios (95% CIs) unless stated otherwise

                                                              Quarters of fatty acids intake   P for trend                                                       
  ----------------------------------------------------------- -------------------------------- --------------------- --------------------- --------------------- ---------
  **Marine n-3 PUFAs** [**\***](#t3n1){ref-type="table-fn"}                                                                                                      
  Median (range) % energy                                     0.03 (≤0.05)                     0.07 (0.06-0.09)      0.13 (0.10-0.17)      0.25 (≥0.17)          
  Cardiovascular disease mortality:                                                                                                                              
   No of cases/person years                                   198/31 217                       169/31 439            166/31 618            113/31 721            
   Model 1[†](#t3n2){ref-type="table-fn"}                     1.00                             0.83 (0.67 to 1.02)   0.78 (0.63 to 0.97)   0.54 (0.42 to 0.68)   \<0.001
   Model 2[‡](#t3n3){ref-type="table-fn"}                     1.00                             0.92 (0.74 to 1.14)   0.91 (0.72 to 1.14)   0.69 (0.52 to 0.90)   0.007
  Total mortality:                                                                                                                                               
   No of cases/person years                                   791/30 674                       703/30 974            606/31 239            402/31 475            
   Model 1[†](#t3n2){ref-type="table-fn"}                     1.00                             0.89 (0.80 to 0.98)   0.77 (0.69 to 0.85)   0.52 (0.46 to 0.59)   \<0.001
   Model 2[‡](#t3n3){ref-type="table-fn"}                     1.00                             0.99 (0.89 to 1.10)   0.91 (0.81 to 1.03)   0.71 (0.62 to 0.82)   \<0.001
  **α-linolenic acid**                                                                                                                                           
  Median (range) % energy                                     0.40 (≤0.45)                     0.49 (0.46-0.54)      0.58 (0.55-0.65)      0.76 (≥0.66)          
  Cardiovascular disease mortality:                                                                                                                              
   No of cases/person years                                   195/31 291                       168/31 509            142/31 578            141/31 616            
   Model 1[†](#t3n2){ref-type="table-fn"}                     1.00                             0.96 (0.78 to 1.18)   0.83 (0.66 to 1.03)   0.84 (0.67 to 1.04)   0.07
   Model 2[‡](#t3n3){ref-type="table-fn"}                     1.00                             1.06 (0.85 to 1.32)   0.98 (0.76 to 1.26)   1.13 (0.85 to 1.51)   0.44
  Total mortality:                                                                                                                                               
   No of cases/person years                                   827/30 715                       680/31 066            510/31 253            485/31 328            
   Model 1[†](#t3n2){ref-type="table-fn"}                     1.00                             0.89 (0.80 to 0.99)   0.69 (0.62 to 0.77)   0.65 (0.58 to 0.73)   \<0.001
   Model 2[‡](#t3n3){ref-type="table-fn"}                     1.00                             0.98 (0.87 to 1.09)   0.80 (0.70 to 0.91)   0.88 (0.76 to 1.02)   0.04
  **Linoleic acid**                                                                                                                                              
  Median (range) % energy                                     3.65 (≤4.21)                     4.72 (4.22-5.13)      5.55 (5.14-6.16)      7.03 (≥6.17)          
  Cardiovascular disease mortality:                                                                                                                              
   No of cases/person years                                   209/31 299                       161/31 509            149/31 545            127/31 641            
   Model 1[†](#t3n2){ref-type="table-fn"}                     1.00                             0.81 (0.66 to 1.00)   0.76 (0.61 to 0.94)   0.67 (0.53 to 0.84)   \<0.001
   Model 2[‡](#t3n3){ref-type="table-fn"}                     1.00                             0.86 (0.69 to 1.07)   0.81 (0.63 to 1.05)   0.75 (0.56 to 1.01)   0.06
  Total mortality:                                                                                                                                               
   No of cases/person years                                   848/30 730                       623/31 096            575/31 163            456/31 373            
   Model 1[†](#t3n2){ref-type="table-fn"}                     1.00                             0.80 (0.72 to 0.88)   0.76 (0.68 to 0.84)   0.62 (0.55 to 0.69)   \<0.001
   Model 2[‡](#t3n3){ref-type="table-fn"}                     1.00                             0.89 (0.80 to 1.00)   0.90 (0.80 to 1.02)   0.81 (0.69 to 0.94)   0.008
  **Arachidonic acid**                                                                                                                                           
  Median (range) % energy                                     0.05 (≤0.06)                     0.07 (0.07-0.08)      0.09 (0.09-0.10)      0.12 (≥0.11)          
  Cardiovascular disease mortality:                                                                                                                              
   No of cases/person years                                   168/31 429                       142/31 531            165/31 533            171/31 502            
   Model 1[†](#t3n2){ref-type="table-fn"}                     1.00                             0.91 (0.73 to 1.14)   1.13 (0.91 to 1.41)   1.16 (0.93 to 1.45)   0.07
   Model 2[‡](#t3n3){ref-type="table-fn"}                     1.00                             0.83 (0.65 to 1.07)   1.05 (0.80 to 1.39)   1.00 (0.71 to 1.39)   0.73
  Total mortality:                                                                                                                                               
   No of cases/person years                                   711/30 946                       599/31 139            621/31 132            571/31 144            
   Model 1[†](#t3n2){ref-type="table-fn"}                     1.00                             0.93 (0.83 to 1.04)   1.01 (0.91 to 1.13)   0.98 (0.88 to 1.10)   0.90
   Model 2[‡](#t3n3){ref-type="table-fn"}                     1.00                             0.91 (0.80 to 1.02)   1.05 (0.91 to 1.21)   1.01 (0.85 to 1.19)   0.64

Sum of eicosapentaenoic acid and docosahexaenoic acid.

Adjusted for age (in months), sex, and survey period.

Further adjusted for ethnicity (white, others), body mass index at diagnosis (\<23.0, 23.0-24.9, 25.0-29.9, 30.0-34.9, ≥35.0), physical activity (0-0.4, 0.5-1.9, 2.0-3.4, 3.5-5.4, ≥5.5 h/week), smoking status (never, past, current 1-14 cigarettes/d, current ≥15 cigarettes/d), smoking pack years (0, \<20, ≥20 pack years), alcohol consumption (0, 0.1-4.9, 5.0-14.9, 15.0-29.9, ≥30.0 g/d), multivitamin use (yes, no), current aspirin use (yes, no), family history of myocardial infarction (yes, no), family history of diabetes (yes, no), history of hypercholesterolemia (yes, no), history of hypertension (yes, no), duration of diabetes (\<5, 5-10, \>10 years), total energy intake (quarters), dietary cholesterol (quarters), and percentage of energy from dietary protein and remaining fatty acids where appropriate (polyunsaturated fatty acids (PUFAs), monounsaturated fatty acids, trans fats, linoleic acid, arachidonic acid, α-linolenic acid, and marine n-3 PUFAs; all continuous variables). In this model, the β coefficients of dietary fats bear meaning of effects of isocalorically substituting for total carbohydrates.

Cancer mortality
----------------

We observed no significant associations of saturated fatty acid and MUFA intake with cancer mortality (supplementary table C). As shown in supplementary table D, participants in the highest quarter of marine n-3 PUFA intake had a 28% (hazard ratio 0.72, 0.53 to 0.99) lower risk of cancer mortality, compared with those in the lowest quarter. Intake of α-linolenic acid was inversely associated with cancer mortality, but the hazard ratio comparing extreme quarters did not achieve statistical significance (0.75, 0.53 to 1.05; P for trend=0.04).

Substitution for saturated fatty acids
--------------------------------------

[Figure 1](#f1){ref-type="fig"} shows mortality risk by isocaloric replacement of saturated fatty acids with other fats. Mortality due to cardiovascular disease was 13% (hazard ratio 0.87, 0.77 to 0.99) lower when 2% energy from saturated fatty acids was isocalorically replaced by total PUFAs and 15% (0.85, 0.73 to 0.99) lower when it was replaced by linoleic acid. Similarly, replacing 2% energy from saturated fatty acids with total PUFAs was associated with 12% (hazard ratio 0.88, 0.83 to 0.94) lower total mortality. We found no significant changes in total mortality (hazard ratio 0.99, 0.94 to 1.05) or cardiovascular disease mortality (0.99, 0.88 to 1.11) when replacing 2% energy from saturated fatty acids with MUFAs. Replacing saturated fatty acids with PUFAs was not associated with cancer mortality (supplementary figure B).

![Multivariate adjusted hazard ratios of cardiovascular disease mortality and total mortality by isocaloric substitution of specific types of dietary fats for saturated fatty acids (SFAs). Model was adjusted for age (in months), sex, survey period, white ethnicity (yes, no), body mass index at diagnosis (\<23.0, 23.0-24.9, 25.0-29.9, 30.0-34.9, ≥35.0), physical activity (0-0.4, 0.5-1.9, 2.0-3.4, 3.5-5.4, ≥5.5 h /week), smoking status (never, past, current 1-14 cigarettes/d, current ≥15 cigarettes/d), smoking pack years (0, \<20, ≥20), alcohol consumption (0, 0.1-4.9, 5.0-14.9, 15.0-29.9, ≥30.0 g/d), multivitamin use (yes, no), current aspirin use (yes, no), family history of myocardial infarction (yes, no), family history of diabetes (yes, no), history of hypercholesterolemia (yes, no), history of hypertension (yes, no), diabetes duration (\<5, 5-10, \>10 years), total energy intake (quarters), dietary cholesterol (quarters), and percentage of energy from dietary protein, carbohydrates, and remaining fatty acids where appropriate (polyunsaturated fatty acids (PUFAs), monounsaturated fatty acids (MUFAs), trans fats, linoleic acid (LA), arachidonic acid (AA), α-linolenic acid (ALA), and marine n-3 PUFAs, all continuous variables)](jiaj048420.f1){#f1}

Sensitivity analyses
--------------------

The associations of specific dietary fats with total, cardiovascular disease, and cancer mortality did not change materially after exclusion of participants with extreme body mass index or further adjustment for the use of hypoglycemic drugs (supplementary table E). Excluding deaths that occurred within four years after diagnosis of type 2 diabetes slightly strengthened the results. We observed similar results when we further adjusted for the use of lipid lowering drugs or restricted the analysis to only incident cases of diabetes. Restricting the analysis to only confirmed cases of type 2 diabetes slightly attenuated the associations.

Discussion
==========

In two cohorts of US men and women, we showed an inverse association of dietary PUFAs, including linoleic acid and marine n-3 PUFAs, with mortality due to cardiovascular disease or total mortality among patients with type 2 diabetes. In addition, animal derived MUFAs were associated with higher total mortality when compared with dietary carbohydrates.

Comparison with other studies and possible explanations
-------------------------------------------------------

To our knowledge, this is the first prospective analysis that investigated the associations between specific dietary fats and cardiovascular disease mortality among people with type 2 diabetes. Our findings on PUFAs are largely ascribed to linoleic acid, which is the most abundant PUFA in the diet.[@ref4] Similarly, a recent analysis in the NHS and HPFS showed a significant inverse association of dietary linoleic acid with total and cardiovascular disease mortality among participants who were free of major chronic diseases, including diabetes, at baseline.[@ref34] However, these findings are seemingly contradictory to evidence from the Sydney Diet Heart Study showing that higher linoleic acid intake led to increased mortality.[@ref35] We note that safflower oil and margarines were used as the food source of linoleic acid in this intervention, so the observed effect may be at least partially ascribed to the high trans fat contents of margarines at that time.[@ref36] In contrast, a recent meta-analysis of four randomized controlled trials showed that substituting PUFAs for saturated fatty acids reduced the risk of coronary heart disease by approximately 30%.[@ref37] Our findings are also in line with a 30 week intervention study that showed that a diet enriched with linoleic acid (10.9% of energy) reduced concentrations of total cholesterol and low density lipoprotein cholesterol among people with type 2 diabetes.[@ref38] Collectively, these data suggest that intake of n-6 PUFAs may exert beneficial effects on cardiovascular health among people with and without type 2 diabetes.

Potential cardiovascular benefits of marine n-3 PUFAs have been reported in numerous cohort studies,[@ref39] [@ref40] although a recent meta-analysis did not show protective effects of marine n-3 supplements on cardiovascular outcomes, including cardiac death.[@ref41] This inconsistency may be due to high baseline dietary marine n-3 PUFA intake, few cardiac deaths, revascularization therapy, and use of statins and other lipid lowering drugs that may mask the effects of a low to moderate dose of fish oil supplementation in patients with cardiovascular disease.[@ref42] In the recent VITAL trial, marine n-3 fatty acid supplementation significantly lowered the risk of cardiovascular disease among participants who had a lower intake of these fatty acids at baseline.[@ref43] Moreover, in the REDUCE-IT trial, which used a high dose (4 g/day) of pure eicosapentaenoic acid supplementation, the risk of developing cardiovascular disease was substantially reduced.[@ref44] Evidence specifically pertinent to patients with diabetes is relatively sparse. Clinical trials looking at intermediate cardiovascular disease outcomes among adults with diabetes have consistently reported that marine n-3 supplements could lower triglyceride concentrations,[@ref45] improve arterial blood flow, and ameliorate inflammatory conditions that predispose cardiovascular disease events.[@ref46] [@ref47] Meanwhile, a secondary analysis of the JELIS study found that eicosapentaenoic acid supplementation (1.8 g/day) for 4.6 years led to a 22% reduction in risk of coronary artery disease among 4565 adults with type 2 diabetes or impaired glucose metabolism,[@ref48] but this effect was not observed in another randomized controlled trial (0.9 g/day) with a larger sample size (n=12 536) and longer follow-up (6.2 years).[@ref49] In the latest trial of 15 480 patients with diabetes, although daily supplementation with 0.84 g marine n-3 PUFAs for 7.4 years did not significantly lower the risk of major vascular events, including non-fatal myocardial infarction or stroke, transient ischemic attack, and vascular death, the vascular deaths were fewer in the marine n-3 fatty acid group than in the control group (rate ratio 0.82, 95% confidence interval 0.68 to 0.98).[@ref7]

The morbidity and mortality of some cancers, such as endometrial, breast, and colorectal cancer is elevated in people with type 2 diabetes.[@ref50] The inverse association of marine n-3 PUFAs and α-linolenic acid with cancer mortality among patients with diabetes is consistent with a previous cohort study reporting that total intake of n-3 PUFAs from diet and supplements was associated with lower cancer mortality in a general population.[@ref51] In addition, meta-analyses have concluded that n-3 PUFA intake was inversely related to risks of developing breast,[@ref52] [@ref53] prostate,[@ref54] or liver cancer.[@ref55] In rodent models, n-3 PUFA supplements also ameliorated the diabetic phenotype and subsequently reduced the risk of colorectal cancer by inhibiting colonic expression of hepatocyte nuclear factor 4α and β-catenin/Tcf.[@ref56]

Diets enriched with MUFAs, in comparison with carbohydrates, have been reported to improve metabolic risk factors in adults with type 2 diabetes.[@ref57] Consistently, substitution of MUFAs for carbohydrates was associated with lower total mortality among people with diabetes in the European Prospective Investigation into Cancer and Nutrition.[@ref58] We have recently reported that the associations of dietary MUFAs with risk of coronary heart disease were dependent on the food sources: MUFAs from plant foods were associated with a lower coronary heart disease risk, whereas their counterparts from animal sources were associated with a higher risk, possibly because of confounding by other food constitutes in animal produts.[@ref59] In the current study, we did not detect significant associations with total or cardiovascular disease mortality for total MUFAs or plant derived MUFAs, but animal based MUFAs were significantly associated with total mortality. Similarly, the Kuopio Ischemic Heart Disease Risk Factor study reported that dietary MUFAs, which were mainly from animal products in the study population, were associated with a higher risk of fatal coronary heart disease.[@ref60] Taken together, these data emphasize the role of food sources in determining the effects of MUFA intake on cardiovascular health in general populations and people with diabetes.

Strengths and limitations
-------------------------

This investigation has the strength of using the repeated assessments of diet after diagnosis of diabetes, which can help to capture potential dietary changes typically observed among people with type 2 diabetes.[@ref12] [@ref58] Other strengths include the relatively large sample size, long term follow-up with a high follow-up rate (\>90%), and repeated measurements of other lifestyle factors. In addition, when we excluded participants who died within four years or those with high body mass index, the results did not change materially, indicating the robustness of our findings.

The study also has limitations. Firstly, glycemic control and severity of diabetes were not rigorously assessed. However, when we adjusted for duration of diabetes in the model and further adjusted for the use of insulin and hypoglycemic drugs, the results remained unchanged. Prevalent cases may differ from incident cases in terms of their risk profiles, but restricting the analysis to incident cases yielded similar results. Secondly, measurement errors in self reported diet and lifestyle factors were inevitable and may attenuate the associations of interest owing to the prospective study design. Thirdly, as in any observational study, we cannot exclude the role of residual confounding due to errors in measurement of covariates adjusted for in the analyses. In addition, we could not rule out unmeasured confounding by adherence to drug treatment, psychosocial stress, or other factors that were not assessed in the cohorts. Despite the shared sources of saturated fats and cholesterol, our findings are independent of dietary cholesterol intake, possibly because the effect of dietary cholesterols on circulating concentrations of cholesterol is relatively small.[@ref61] We also controlled for self reported hypercholesterolemia and use of lipid lowering drugs, and results did not change materially, suggesting that these factors may not fully account for the associations that we observed. Lastly, causality may not be established because of the observational nature of this study.

Conclusions and implications
----------------------------

Among US men and women with type 2 diabetes, dietary intake of PUFAs, especially linoleic acid and marine n-3 PUFAs, is associated with lower total and cardiovascular disease mortality. Our results suggest that dietary PUFAs, in replacement of saturated fatty acids or carbohydrates, may facilitate long term survival among adults with type 2 diabetes.

### What is already known on this topic

1.  Dietary guidelines for patients with diabetes recommend limiting trans fat intake and replacing saturated fats with unsaturated fats for maintaining good health

2.  These recommendations are largely based on findings in general populations

3.  Little is known about the associations of specific dietary fats with total and cardiovascular disease mortality among patients with diabetes who have altered metabolism of macronutrients

### What this study adds

1.  Among diabetes patients, higher dietary intake of total polyunsaturated fatty acids (PUFAs), α-linolenic acid, linoleic acid, and marine n-3 PUFAs is associated with lower total mortality

2.  Intake of monounsaturated fats from animal sources is associated with higher total mortality

3.  In an isocaloric model, theoretically replacing saturated fatty acids with PUFAs, especially linoleic acid, is associated with lower cardiovascular disease mortality

4.  Increasing dietary PUFAs, especially linoleic acid and marine n-3 PUFAs, in replacement of saturated fatty acids, may facilitate long term survival among patients with diabetes
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